PFIZER INC. for PFIZER INC.
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report (this page) | Jan 20, 2010 | $5,590,000 | Replaced |
| 4th Quarter - Report | Jan 26, 2010 | $5,590,000 | Replaced |
| 4th Quarter - Amendment | Sep 21, 2010 | $6,200,000 | Yes |
What was lobbied
10 issue areas, each in the filer's own words, with who lobbied on it and where.
Labor Issues/Antitrust/Workplace LBR
Wyeth Acquisition
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN PAUL HALLIWELL | — |
| LOUIS A LAMARCA | — |
| ANTHONY PRINCIPI | — |
| ANGELA WALKER RIEMER New | — |
Trade (domestic/foreign) TRD
US- China Trade Dialogues (JCCT) - market access and IP issues Trans Pacific Partnership talks US - EU Dialogues (TEC) - market access and regulatory issues Japan Market Access and Regulatory Issues US-Korea Free Trade Agreement (no bills) US-Peru Free Trade Agreement (no bills) US-Columbia Free Trade Agreement (no bills) US-Panama Free Trade Agreement (no bills) Norway Patent issues (no bills) Poland market access (no bills) Russia market access (no bills) Turkey Market Access (no bills) Free Trade Agreement Implementation Legislation (Peru, Columbia, Panama, Korea, Israel, Saudi Arabia) OECD Accession Saudi Arabia Patent Issues (no bills) South Africa Pricing & Patent Issues (no bills) Israel Patent Issues (no bills) Finland Patent Issues Taiwan - Market Access Issues (TIFA talks) APEC Life Sciences Innovation Forum Mexico IP and market access issues Brazil IP Thailand Compulsory Licensing India IP and market access issues Australian FTA Implementation Special 301 Reform Legislation Trade Enforcement Legislation
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSEPH DAMOND | — |
| STEPHANIE HENNING | — |
| ANTHONY PRINCIPI | — |
Agriculture AGR
H.R. 2400 - Strategies to Address Antimicrobial Resistance Act H.R. 1549 - The Preservation of Antibiotics for Medical Treatment Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN PAUL HALLIWELL | — |
| ANTHONY PRINCIPI | — |
Taxation/Internal Revenue Code TAX
H.R. 198 - Healthcare Tax Deduction Act of 2009 H.R. 422 - R&E tax credit extension and Enhancement H.R. 2098 - CFC Look Through Extension S. 1203 - R& E tax credit extension and Enhancement Deferral Deferral for active-financing income- extension Tax Treaties - France, New Zealand, Malta
| Lobbyist | Covered position, as disclosed |
|---|---|
| KIMBERLY JANE PINTER | — |
| ANTHONY PRINCIPI | — |
Consumer Issues/Safety/Products CSP
S.80 - Pharmaceutical Market Access Act, 1/09 S. 501 - Fair prescription Drug Competition Act, 3/09 S. 767 - Independent Drug Education and Outreach Act, 4/09 S. 882 - Drug and Device Accountability Act H.R. 163 - The Prescription Drug Affordability Act, 1/09 H.R. 91 - Shipment of Prescription Drugs between the States and the Virgin Islands, 1/09 H.R. 573 - act to prohibit the marketing of authorized generic drugs, 1/09 H.R. 1427 - Promoting Innovation and Access to Life-Saving Medicines Act, 3/09 H.R. 1548 - Pathway for Biosimilars Act, 3/09 H.R. 759 - The Food, drug and Cosmetic Globalization Act, 1/09 H.R. 1256 - Family Smoking Prevention: Tobacco Control Act H.R. 1259 - Dextromethorphan Distribution Act 4/09 S. 1383 - Dextromethorphan Abuse Reduction Act 6/09
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN PAUL HALLIWELL | — |
| LOUIS A LAMARCA | — |
| ANTHONY PRINCIPI | — |
| ANGELA WALKER RIEMER New | — |
Copyright/Patent/Trademark CPT
S. 515 - Patent Reform Act of 2009 S. 299 - Expert Patent Courts Pilot Program Act, 1/09 S. 369 - Preserve Access to Affordable Generics, 2/09 S. 515 - Patent Reform Act, 3/09 S.610 - Patent Reform Act, 3/09 H.R. 1260 - Patent Reform Act, 3/09 H.R. 1706 - Protecting Consumer Access to Generics Drug Act, 3/09 H.R. 1548 - Pathway for Biosimilars Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSEPH DAMOND | — |
| JOHN PAUL HALLIWELL | — |
| LOUIS A LAMARCA | — |
| ANTHONY PRINCIPI | — |
Budget/Appropriations BUD
Administration budget proposal, deferral and other international tax issues H.R.3293 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2010
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSEPH DAMOND | — |
| BRONWEN KAYE New | — |
| KIMBERLY JANE PINTER | — |
| ANTHONY PRINCIPI | — |
Defense DEF
H.R. 1256 - Family Smoking and Prevention and Tobacco Control Act VA Drug Coverage Smoking Cessation Coverage
| Lobbyist | Covered position, as disclosed |
|---|---|
| LOUIS A LAMARCA | — |
Health Issues HCR
Veterans Healthcare issues Health Reform Comparative Effectiveness Research Health Information Technology S. 4 - Comprehensive Health Reform Act (1/09) S. 45 - Health Liability Reduction Act (1/09) S. 301 - Physician Payments Sunshine Act (1/09) S. 501 - Fair Prescription Drug Competition Act (3/09) S. 726 - Promoting Innovation and Access to Life-Saving Medicine Act S. 717 - 21st Century Cancer ALERT Act S. Con Res 13 - Budget Reconciliation H.R. 15 - National Health Insurance Act (1/09) H.R. 193 - AmeriCare Act (1/09) H.R. 1 - The American Recovery and Reinvestment Act H.R. 1427 - Promoting Innovation and Access to Life-Saving Medicine Act H.R. 2 - Children's Health Insurance Program Reauthorization Act of 2009 H.R. 1548 - Pathway for Biosimilars Act H. Con Res 85 - Budget Reconciliation H.R. 2366 Cancer Drug Coverage Parity Act 0f 2009 H.R. 1548 - The Pathway for Biosimilars Act H.R. 1549 The Preservation of Antibiotics for Medical Treatment Act H.R. 2400 - Strategies to Address Antimicrobial Resistance Act H.R. 3200 - America's Affordable Health Choice Act H.R. 2366 - Cancer Drug Coverage parity Act H.R. 3962 - Affordable Healthcare for America Act H.R. 3590 - Patient Protection and Affordable Care Act Health Information Technology Comparative Effectiveness Research Health Care Reform Proposals Follow on Biologics Medicare Part D
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA BISHOP-MURPHY | — |
| CHRISTOPHER CAREY | — |
| MARIA CINO | Assistant Secretary & Director General of USFCS |
| JOHN PAUL HALLIWELL | — |
| BRONWEN KAYE New | — |
| LOUIS A LAMARCA | — |
| ANTHONY PRINCIPI | — |
| ANGELA WALKER RIEMER New | — |
Medicare/Medicaid MMM
H.R. 684 - The Medicare Prescription Drug Savings and Choice Act of 2009 H.R. 574 - Medicare Home Infusion Therapy Coverage Act of 2009 S. 75 - Generics First Act of 2009 (Part D) H.R. 2502 - Comparative Effectiveness Research Act H.R. 3200 - America's Affordable Heath Choices Act of 2009. H.R. 3675 - National Quality Cancer care Demonstration Project Act of 2009 S. 1630 - Affordable Access to Prescription Medicine Act of 2009 S. 1679 - Affordable Heath Choices Act of 2009 Medicare Prescription Drug Benefit Implementation Medicaid Rebates Medicare Coverage Average Manufacturer Price Regulation Medicare Secondary Payer Guidance
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER CAREY | — |
| JOHN PAUL HALLIWELL | — |
| ANTHONY PRINCIPI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.